The market is trading the cycle. The real underwriting variable is the post-OBBBA Medicaid pool.

• Cycle question, well-priced. Q1 2026 stepped consolidated MCR from 91.7% to 91.1%; adjusted EPS beat consensus by 50% ($2.35 vs $1.57); 5 upward 2026 EPS revisions and zero cuts since. BofA double-upgraded to Buy at $250. Bulls and bears both converge on the Q3 2026 print as the cycle verdict.
• Durable question, unpriced. OBBBA work requirements permanently remove 15–20% of the 1.2M Medicaid Expansion population by 2029; ACA enhanced subsidies expired 12/31/2025, forcing a ~50% Marketplace cut. Whether the protected revenue base settles near $40–42B or $35–37B is what decides 2029 EPS.
• One state, one calendar. Washington Medicaid is $4.2B and 13% of Medicaid premium. The RFP files Q4 2026 with an award expected mid-to-late 2027. A second loss after the Virginia precedent would rebase the RFP win-rate prior from compounding to eroding.

A 70% drawdown, a covenant amendment, and a securities class action.

Before: Through 2018–2024, Molina compounded a ~33% average ROE on a regulated, capital-light Medicaid franchise. The stock ran from ~$49 in mid-2016 to a $420 March 2024 peak on the post-PHE redetermination tailwind and a series of tuck-in Medicaid acquisitions; cumulative RFP renewals and new wins plus acquisitions added $10B+ of premium revenue over 2019–2025 (FY25 10-K).

Break: The 2024 rate book underestimated medical-cost trend by 250bps for two consecutive years. FY25 adjusted EPS landed at $11.03 against an initial $24.50 guide — three guidance cuts inside twelve months. Operating margin fell from 4.2% to 1.7%; operating cash flow turned negative $535M, the first negative year since 2018.

Today: Q1 2026 stepped MCR to 91.1%; the Florida sole-source Children's Medical Services / CMS award (~$6B run-rate premium) and the Illinois Medicaid managed-care award (1/1/2027 start) landed during the trough. FY26 Medicaid MCR guide of 92.9% sits above the FY25 Medicaid trough of 91.8%, and on 2/4/2026 lenders amended the interest-coverage covenant — from a 3.00x threshold to 1.75x for the rest of FY26, stepping up to 2.00x in Q1'27, 2.50x in Q2'27, and 2.75x in Q3'27.

Every 100bps of MCR is roughly $430M pretax. The cycle moved the dial 350bps.

Premium revenue is set by state actuaries; G&A is largely fixed; the single discretionary lever is medical-cost control. The 2017 episode was a Marketplace miss on a thin slice of the book and recovered in 12 months. The 2025 episode is a Medicaid miss on 75% of the book, layered on top of OBBBA. Management's FY26 EPS floor is $5; management's 2029 target is $25 with BofA's bull case at $30 against Street consensus of $17.32. The gap between $5 trough and $20–25 normalized — on the same 51M share count — is the underwriting variable.

Florida and Mississippi proved the franchise held during the worst earnings year.

• Lowest G&A in the peer set. 6.4% adjusted G&A versus Centene 8.4%, Elevance 11.2%, Humana 11.8%, UnitedHealth 13.6%. No PBM, no care delivery, no commercial book to absorb. The structural gap drives bid math at every state RFP.
• Won head-to-head while bleeding. The Mississippi Medicaid contract commenced 7/1/2025; Florida selected Molina as the sole plan for the statewide Children's Medical Services / CMS program on 11/14/2025 (~$6B run-rate premium); the Illinois Medicaid managed-care contract was awarded 6/10/2026 for 1/1/2027 start. The 10-K cites roughly $9B of incremental annual premium revenue contracted from 2025 RFP awards plus the ConnectiCare acquisition.
• Concentrated, contract-by-contract. California, New York, Texas, and Washington each carry ≥10% of Medicaid premium — together 54% of the Medicaid book. Virginia's April 2024 loss removed $1B effective 6/30/2025. The moat is the franchise; the franchise is four state contracts.

The buyback program retired roughly $2B of stock with the most recent $500M tranche done at $297.83/share while the stock today is $198.

• Buybacks at the wrong price. $1.06B repurchased FY24 plus $1.04B FY25 (FY25 split between $500M at $297.83/sh in Q1 and $500M at $175.50/sh in Q3 per the 10-K), partly funded by $1.94B of new senior notes including $850M of 6.500% notes due 2031. Debt/EBITDA ran from prior-cycle ~1–2x levels to 3.7x at FY25 year-end and 6.1x at Q1 2026 as trailing EBITDA fell.
• Reserves possibly set light. FY26 Medicaid MCR guide of 92.9% sits above the FY25 Medicaid actual of 91.8%, while Days in Claims Payable compressed to 44 at Q1 2026 (from 47 at FY25 year-end and a 45–50 historical norm). In a typical cycle recovery the reserve cushion rebuilds before MCR falls. The current configuration is the opposite.
• Mixed insider tape, 40% say-on-pay. A Yahoo Finance / Simply Wall St item on 3/9/2026 characterized the CFO, COO, EVP and CLO as having made substantial insider purchases, but the underlying March 1, 2026 Form 4s describe equity-plan grants with tax-withholding dispositions rather than cash open-market buys (only confirmed open-market buy at the trough was 800 shares for $100,128 on 2/11/2026). CLO Barlow then sold 17,811 shares on 5/11/2026 (~$3.31M) during active Hindlemann securities litigation. The April 2025 say-on-pay vote received only 40% support — far below the >90% range of prior years.